| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328284 | Acta Haematologica Polonica | 2014 | 6 Pages |
Abstract
Primary myelofibrosis (PMF) is a Ph-negative myeloproliferative neoplasm (MPN), that manifests bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. The conventional therapeutic options for patients with PMF consist of management of anemia, use of cytoreductive and immunomogulatory agents, and splenectomy or splenic irradiation. Cure is only achievable through allogeneic haematopoietic stem cell transplantation. The discovery of crucial role of JAK2 signaling in pathogenesis of PMF has resulting in new JAK2 inhibitor therapy, such ruxolitinib or other investigated molecules.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Maria Cioch, PaweÅ Jarosz,